PPIE in clinical trials at scale: analysis of the first 3,250 responses on the POrtal for Patient and Public Engagement in Dementia (POPPED)
Qin, H.; Pointon, L.; Carpenter, J.; Raymont, V.; Dunne, R.; Reeves, S.; Ali, S.; Iqbal, S.; Bonet-Olivares, C.; Whittle, J.; Rizzo, L.; Malhotra, P.; Underwood, B. R.
Show abstract
INTRODUCTIONPatient and public involvement and engagement (PPIE) is essential for improving research but is often limited in scale. This study explored the potential for large-scale involvement using a web-based approach. METHODSWe created an online portal to collect feedback on dementia research and sought views on the forthcoming UK-based adaptive platform trial testing repurposed drugs for Alzheimers disease (AD-SMART). Participants completed a survey with a ranking task for four anonymized drugs prioritised for inclusion and discrete choice experiments (DCEs) on treatment attributes trade-offs. RESULTSResponses from over 3,250 people across 27 countries and 6 continents strongly supported for the trial. Metformin was the most preferred, followed by Atomoxetine, Isosorbide Mononitrate, and Levetiracetam. Safety ranked highest, followed by evidence of efficacy and convenience. Analyses were stratified by sex, age, and dementia experience. DISCUSSIONWeb-based PPIE can effectively inform dementia research at scale and offers a transferable model for other studies.
Matching journals
The top 9 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Top-funded digital health companies offering lifestyle interventions for dementia prevention: Company overview and evidence analysis 94%
- Identifying incident dementia by applying machine learning to a very large administrative claims dataset 94%
- Randomized Clinical Trial of ICECaP (Individualized Coordination and Empowerment for Care Partners of Persons with Dementia): Primary Mental Health and Burden Outcomes 93%
Similar papers in this journal
- Preventable deaths involving medicines in England and Wales, 2013-22: a systematic case series of coroners’ reports 91%
- Standardization of drug names in the FDA Adverse Event Reporting System: The DiAna dictionary 90%
- Patient-Reported Reasons for Antihypertensive Medication Change: A Quantitative Study Using Social Media 90%
Similar papers in this journal
- Exploring the Feasibility of Using Real-World Data from a Large Clinical Data Research Network to Simulate Clinical Trials of Alzheimer’s Disease 95%
- Machine Learning Prediction of Incidence of Alzheimers Disease Using Large-Scale Administrative Health Data 93%
- A scoping review of remote and unsupervised digital cognitive assessments in preclinical Alzheimer’s disease 92%
Similar papers in this journal
- Returning Research Results That Indicate Risk of Alzheimer Disease Dementia to Healthy Participants in Longitudinal Studies (WeSHARE) 93%
- Digital Health Technologies for Metabolic Disorders in Older Adults: A Scoping Review Protocol 92%
- Developing a core outcome set for interventions in people with mild cognitive impairment: study protocol 92%
Similar papers in this journal
- A Qualitative Study of People with Alzheimer’s Disease in a Memory Clinic Considering Lecanemab Treatment 94%
- Non-pharmaceutical interventions for persons living with young-onset dementia and their informal caregivers: a systematic review with meta-analysis 93%
- Harnessing Greater Statistical Power: Comprehensive Evaluation of Disease Modifying Treatment Effects Across All or Multiple Post-Baseline Visits Compared to the Last Visit for Alzheimer’s Disease Clinical Trials 92%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.